Adenocarcinoma of Prostate Clinical Trial
Official title:
Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer.
Investigators compare in a randomized clinical trial the results and side effects of high-dose- and low-dose-rate brachytherapy as monotherapy in the treatment of early, organ confined prostate cancer patients.
Permanent implant prostate brachytherapy (LDRPBT) is a well established and proved method in
the treatment of patients with low or selected intermediate risk, organ confined prostate
cancer.
There are number of studies with high-dose rate brachytherapy (HDRPBT) as monotherapy with
several fractionation schedule treating the same group of patients. One phase II trial
showed its effectiveness given in one fraction of 19 Gy.
In the trial investigators randomly select patients to treat with either LDR prostate
brachytherapy (145Gy) or HDR prostate brachytherapy (1x19Gy) as monotherapy.
Patients are stratified into two pretreatment group: 1. low risk, 2. selected intermediate
risk group.
Brachytherapy is given in spinal anaesthesia, using transrectal ultrasound based real time
treatment planning. Dose constraints are defined for both methods.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
Recruiting |
NCT02672449 -
Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer
|
N/A | |
Completed |
NCT02342626 -
Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT01913717 -
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
|
N/A | |
Completed |
NCT02025361 -
Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy
|
Phase 4 | |
Completed |
NCT00140478 -
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01952223 -
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
|
Phase 3 | |
Completed |
NCT03518853 -
Short Course Radiotherapy for Localized Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT01994239 -
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
|
Phase 2 | |
Terminated |
NCT02024685 -
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial
|
N/A |